None listed
Conditions
Interventions
Intervention1: Nor-ursodeoxycholic acid tablets 500 mg: Study will be conducted in 3 cohorts. Subjects will receive Single dose of 500 mg in Cohort-I, Single dose of 1000 mg in cohort-II and Single do
Sponsors
Shilpa Medicare Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1) Age: 18 to 45 years old, both inclusive. 2) Gender: Male and/or non-pregnant, non-lactating female. A. Female of childbearing potential must have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test performed within 28 days prior to dosing day. They must be using an acceptable form of contraception. B. For female of childbearing potential, acceptable forms of contraception include the following: i. Non hormonal intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or ii. Barrier methods containing or used in conjunction with a spermicidal agent, or iii. Surgical sterilization or iv. Practicing sexual abstinence throughout the course of the study. C. Female will not be considered of childbearing potential if one of the following is reported and documented on the medical history: i. Postmenopausal with spontaneous amenorrhea for at least one year, or ii. Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or iii. Total hysterectomy and an absence of bleeding for at least 3 months. 3) BMI: 18.5 to 30.0 kg/m2, both inclusive; BMI value should be rounded off to one significant digit after decimal point (e.g. 30.04 rounds down to 30.0, while 18.45 rounds up to 18.5). 4) Able to communicate effectively with study personnel. 5) Willing to provide written informed consent to participate in the study. 6) All volunteers must be judged by the principal or sub-investigator or physician as normal and healthy during a pre-study safety assessment performed within 28 days of study medication which will include: a) A physical examination (clinical examination) with no clinically significant finding. b) Results within normal limits or clinically non-significant for the following tests: Hematology - Hemoglobin, Total RBC count, Total WBC count, Platelet count, Differential leukocyte count and HCT Biochemistry - BUN, Serum creatinine, Random glucose, SGPT & SGOT, Alkaline phosphatase, Uric acid, Serum bilirubin, Total proteins, Albumin & Serum electrolytes Urinalysis - Color, quantity, specific gravity, odour, appearance, reaction, albumin, bilirubin, ketone bodies, sugar, urobilinogen and microscopical examination (performed based on clinical judgment) Immunological Tests - HIV-I & II, HbsAg, Syphilis (RPR), Anti HCV & Serum (β-HCG) pregnancy test (for female of child bearing potential) - Additional tests and/or examinations (apart from mentioned in protocol) may be performed, if necessary, based on principal investigator discretion. - All results will be assessed against the current laboratory normal ranges at the time of testing and a copy of the normal ranges used will be included in the study documentation.
Exclusion criteria
Exclusion criteria: 1) History of allergic responses to Nor-ursodeoxycholic acid, ursodeoxycholic acid or other related drugs, or any of its formulation ingredients. 2) Have significant diseases or clinically significant abnormal findings during screening [medical history, physical examination (clinical examination), laboratory evaluations, abdominal ultrasonography recordings, ECG, chest X-ray recording, gynecological history and examination (including pelvic examination and routine breast examination) (for female volunteers)]. 3) Any disease or condition like diabetes, psychosis or others, which might compromise the haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system or any other body system. 4) History or presence of bronchial asthma. 5) Use of any hormone replacement therapy within 3 months prior to the dose of study medication. 6) A depot injection or implant of any drug within 3 months prior to the dose of study medication. 7) Use of CYP enzyme inhibitors or inducers within 30 days prior to the dose of study medication. 8) History or evidence of drug dependence or of alcoholism or of moderate alcohol use. 9) Smokers who smoke 10 or more cigarettes per day or 20 or more biddies per day or those who cannot refrain from smoking during the study period. 10) History of difficulty with donating blood or difficulty in accessibility of veins. 11) A positive hepatitis screen (includes subtypes B & C). 12) A positive test result for HIV antibody and / or syphilis (RPR). 13) Volunteers who have received a known investigational drug within seven elimination half-life of the administered drug prior to the housing. 14) Volunteers who have donated blood or loss of blood 50 ml to 100 ml within 30 days or 101 ml to 200 ml within 60 days or >200 ml within 90 days (excluding volume drawn at screening for this study) prior to dosing of study medication, whichever is greater. 15) History of difficulty in swallowing or of any gastrointestinal disease, which could affect drug absorption. 16) Intolerance to venipuncture 17) Any food allergy, intolerance, restriction or special diet that, in the opinion of the principal investigator or sub-investigator, could contraindicate the volunteerâ??s participation in this study. 18) Institutionalized volunteers. 19) Use of any prescribed medications within 14 days prior to housing. 20) Use of any OTC products, vitamin and herbal products, etc., within 7 days prior to housing. 21) Use of grapefruit and grapefruit containing products within 7 days prior to housing. 22) Ingestion of any caffeine or xanthine products (i.e. coffee, tea, chocolate, and caffeine containing sodas, colas, etc.), cigarettes and tobacco containing products, recreational drugs, alcohol or other alcohol containing products within 96 hours prior to housing. 23) Ingestion of any unusual diet, for whatever reason (e.g.: low sodium) for three weeks prior to housing.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of study drug-related DLTs (Safety) and assessment of tolerability after single dose administration at dose levels of 500mg and 1000mg and 1500 mgTimepoint: A total of 34 venous blood samples will be collected in each Cohort. Blood samples will be collected at -48.0, -42.0, -36.0, -30.0, -24.0, -18.0, -12.0, -6.0, pre-dose (0.0) hours prior to dosing and at 0.083 (5 minute), 0.167 (10 minute), 0.333 (20 minute), 0.5 (30 minute), 0.667, 0.833, 1.0, 1.167, 1.334, 1.5, 1.667, 1.834, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0 and 72.0 hours post dose. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetic parameters will be calculated on below 1. Pharmacokinetic parameters at dose level 2. Primary Pharmacokinetic parameters at each dose level Cmax, AUC0-t and AUC0-inf 3. Secondary Pharmacokinetic parameters at each dose level Tmax, Kel, AUC%extrapolation, CL, Vd and t1/2 4. Dose proportionalityTimepoint: A total of 34 venous blood samples will be collected in each Cohort. Blood samples will be collected at -48.0, -42.0, -36.0, -30.0, -24.0, -18.0, -12.0, -6.0, pre-dose (0.0) hours prior to dosing and at 0.083 (5 minute), 0.167 (10 minute), 0.333 (20 minute), 0.5 (30 minute), 0.667, 0.833, 1.0, 1.167, 1.334, 1.5, 1.667, 1.834, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0 and 72.0 hours post dose. | — |
Countries
India
Contacts
Public ContactP Veerendra Kumar
Cliantha Research Limited
Outcome results
None listed